Table 2.
Associations between demographic and clinical factors and baseline pNfL values.
| Beta (95% CI) (N = 111) | Percentage change in pNfLa(95% CI) (N = 111) | p-value | |
|---|---|---|---|
| Ageb | −0.043 (−0.113, 0.027) | −4.2 (−10.7, 2.7) | 0.23 |
| Male sexc | −0.036 (−0.354, 0.281) | −3.6 (−29.8, 32.4) | 0.82 |
| Body mass index | −0.018 (−0.058, 0.021) | −1.8 (−5.6, 2.1) | 0.36 |
| EDSS score | 0.109 (−0.057, 0.274) | 11.5 (−5.5, 31.5) | 0.20 |
| Relapse < 120 days agod | 0.091 (−0.218, 0.399) | 9.5 (−19.6, 49.1) | 0.56 |
| MS disease duration relative to randomizationb | −0.068 (−0.135, −0.001) | −6.5 (−12.6, −0.1) | 0.048 |
| Number of Gd-enhancing lesions | 0.048 (0.025, 0.071) | 4.9 (2.6, 7.4) | <0.01 |
| T2 lesion volumee | 0.347 (0.143, 0.551) | 41.5 (15.3, 73.6) | <0.01 |
Multivariable linear regression analysis of log-transformed pNfL concentration values was used to examine association with the variables listed above. Numbers in bold indicate statistical significant association (p < 0.05) between the variable and the baseline pNFL value.
Beta coefficients were back-transformed and converted to a percentage for interpretation; values represent percentage increase/decrease in pNfL per unit change of the independent variable for continuous variables or relative to the reference group for categorical variables. Disease duration was calculated as the difference between date of first MS symptoms and randomization date.
Per year.
Reference is female sex.
Reference group is relapsed ⩾120 days ago.
Cubic root.
CI = confidence interval; EDSS = Expanded Disability Status Scale; Gd = gadolinium; MS = multiple sclerosis; pNfL = plasma neurofilament light chain.